Sintx Technologies issues business update following strategic realignment

SINTX Technologies (SINT) issued a business update in connection with the filing of the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission. “SINTX is now positioned to lead the next wave of innovation in medical technology,” said Eric Olson, Chairman and CEO. “In just six months, we have rebuilt the Company from the ground up-bringing in world-class leadership, streamlining operations, divesting non-core assets, and executing a focused commercialization strategy designed to deliver breakthrough medical solutions and create substantial shareholder value. We are one of the only companies worldwide with both the intellectual property and manufacturing expertise to deliver advanced silicon nitride biomaterials in multiple formats to the medical device industry.”